|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM20123145X |
| 003 |
DE-627 |
| 005 |
20231223222032.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2010 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.07.012
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0671.xml
|
| 035 |
|
|
|a (DE-627)NLM20123145X
|
| 035 |
|
|
|a (NLM)20805041
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Liu, Ying
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity
|
| 264 |
|
1 |
|c 2010
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.02.2011
|
| 500 |
|
|
|a Date Revised 25.11.2016
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2010 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Tim-3 has been reported as an important regulatory molecule and plays a pivotal role in several autoimmunity diseases. Here, we demonstrated the increased expression of Tim-3 on peripheral CD4(+) T, CD8(+) T, NKT cells and monocytes from RA patients compared to those from healthy controls. Percentage of Tim-3(+) cells in peripheral blood mononuclear cells (PBMCs) showed an inverse correlation with disease activity score 28 (DAS28) and plasma TNF-α level. Similar negative correlations were found between disease activity and Tim-3 levels on CD4(+) T, CD8(+) T and NKT cells. Consistently, Tim-3 expression on CD3(+) T cells was further increased in patients with disease remission after treatment. Tim-3 expression on CD8(+) T and NKT cells negatively correlates with plasma TNF-α. Our results suggest that Tim-3 might participate in the proceeding of RA by its negative regulation on various T cell subsets. Tim-3 might be a potential new marker for assessing severity of RA
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Monoclonal, Humanized
|2 NLM
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a HAVCR2 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Hepatitis A Virus Cellular Receptor 2
|2 NLM
|
| 650 |
|
7 |
|a Membrane Proteins
|2 NLM
|
| 650 |
|
7 |
|a Tumor Necrosis Factor-alpha
|2 NLM
|
| 650 |
|
7 |
|a tocilizumab
|2 NLM
|
| 650 |
|
7 |
|a I031V2H011
|2 NLM
|
| 650 |
|
7 |
|a Methotrexate
|2 NLM
|
| 650 |
|
7 |
|a YL5FZ2Y5U1
|2 NLM
|
| 700 |
1 |
|
|a Shu, Qiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gao, Lifen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hou, Nan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Di
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Xiao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Xiaoning
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Liyun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yue, Xuetian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhu, Faliang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Guo, Chun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liang, Xiaohong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ma, Chunhong
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 137(2010), 2 vom: 01. Nov., Seite 288-95
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:137
|g year:2010
|g number:2
|g day:01
|g month:11
|g pages:288-95
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.07.012
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 137
|j 2010
|e 2
|b 01
|c 11
|h 288-95
|